Sc. Duck et R. Rapaport, Long-term treatment with GHRH [1-44] amide in prepubertal children with classical growth hormone deficiency, J PED END M, 12(4), 1999, pp. 531-536
A cohort of 20 GH deficient prepubertal patients were treated with GHRH [1-
44] 10 mu g/kg or 20 mu g/kg twice daily for up to four years (5 patients).
GHRH treatment resulted in sustained improvement in height velocity. The m
ean prepubertal height velocity was 3.57 +/- 1.05 cm/yr pretreatment; 8.49
+/- 1.45 cm/yr at year 1; 6.86 +/- 1.45 cm/yr at year 2; 6.22 +/- 0.74 cm/y
r at year 3; and 6.16 +/- 0.97 cm/yr at year 4, IGF-I levels increased and
remained within normal range. The difference between the children's and the
parents' Ht SD scores significantly diminished from a pretreatment differe
nce of -2.43 to -0.48 after four years of treatment. No adverse effects wer
e noted during treatment. We conclude that twice-daily GHRH [1-44] treatmen
t in a small group of prepubertal GH deficient children resulted in sustain
ed improvement in height and growth velocity, and achieved height SDS appro
aching closely those of their parents.